P. Atadja

P. Atadja, H. Pass, L. Zawel, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma

P. Atadja, A. Pandiella, E. de Álava, 2010, Haematologica.

Differential effects of transforming growth factor-β1 on the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in young and old human fibroblasts

P. Atadja, K. Riabowol, D. Edwards, 1996, Experimental Gerontology.

Therapeutics , Targets , and Chemical Biology NSD 2 Is Recruited through Its PHD Domain to Oncogenic Gene Loci to Drive Multiple Myeloma

P. Atadja, E. Li, Jun Liu, 2013 .

The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells.

P. Atadja, R. Jove, Y. Yen, 2007, Blood.

A potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3).

Xi-Ping Huang, B. Roth, P. Atadja, 2015, Angewandte Chemie.

Loss of Serum Response Factor Activity Is the Basis of Reduced C-FOS Expression in Aging Human Fibroblasts

P. Atadja, K. Riabowol, 1996, Canadian Journal on Aging / La Revue canadienne du vieillissement.

Loss of serum response element-binding activity and hyperphosphorylation of serum response factor during cellular aging

P. Atadja, K. Riabowol, K. Stringer, 1994, Molecular and cellular biology.

The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity

P. Atadja, D. Woods, E. Seto, 2013, Melanoma research.

FXR1 regulates transcription and is required for growth of human cancer cells with TP53/FXR2 homozygous deletion

Z. Weng, P. Atadja, E. Li, 2017, eLife.

Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T‐cell lymphoma models: Defining molecular mechanisms of resistance

P. Atadja, S. Fawell, W. Shao, 2010, International journal of cancer.

The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efﬁcacy

Jessica E. Bolden, S. Lowe, A. Strasser, 2009 .

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies

P. Atadja, K. Bhalla, D. DeAngelo, 2013, Leukemia.

The HDAC Inhibitor LBH589 Enhances the Antimyeloma Effects of the IGF-1RTK Inhibitor Picropodophyllin

O. Larsson, P. Atadja, M. Axelson, 2012, Clinical Cancer Research.

Cancer Therapy : Preclinical The HDAC Inhibitor LBH 589 Enhances the Antimyeloma Effects of the IGF-1 RTK Inhibitor Picropodophyllin

O. Larsson, P. Atadja, M. Axelson, 2012 .

The HDAC inhibitor LBH 589 enhances the anti-myeloma effects of the IGF-1 RTK inhibitor picropodophyllin

O. Larsson, P. Atadja, M. Axelson, 2012 .

Discovery of Potent and Selective Allosteric Inhibitors of Protein Arginine Methyltransferase 3 (PRMT3)

P. Atadja, E. Li, F. Liu, 2017, Journal of medicinal chemistry.

INHIBITION OF HISTONE DEACETYLASE 6 ACETYLATES AND DISRUPTS THE CHAPERONE FUNCTION OF HEAT SHOCK PROTEIN 90: A NOVEL BASIS OF ANTILEUKEMIA ACTIVITY OF HISTONE DEACETYLASE INHIBITORS

J. Bradner, P. Atadja, K. Bhalla, 2005 .

SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells

P. Atadja, R. Jove, A. Scuto, 2013, Cell Death and Disease.

Role of CAAT/Enhancer Binding Protein Homologous Protein in Panobinostat-Mediated Potentiation of Bortezomib-Induced Lethal Endoplasmic Reticulum Stress in Mantle Cell Lymphoma Cells

P. Atadja, K. Bhalla, J. Tao, 2010, Clinical Cancer Research.

Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia.

P. Atadja, O. Ottmann, S. Remiszewski, 2004, Haematologica.

leukemia cells DNA damage response genes and apoptosis in Ph- acute lymphoblastic The novel histone deacetylase inhibitor, LBH589, induces expression of

P. Atadja, R. Jove, Y. Yen, 2013 .

Synergistic Cytotoxic Effects of a Combination of a Novel Tyrosine Kinase Inhibitor AMN107 and Histone Deacetylase Inhibitor LBH589 Against Bcr-Abl Expressing Human Leukemia Cells.

P. Atadja, A. Scuto, S. Annavarapu, 2004 .

Loss of Wdr5 attenuates MLL-rearranged leukemogenesis by suppressing Myc targets.

P. Atadja, Y. Dou, Yan Zhang, 2022, Biochimica et biophysica acta. Molecular basis of disease.

Biocatalytic Synthesis and Structure Elucidation of Cyclized Metabolites of the Deacetylase Inhibitor Panobinostat (LBH589)

P. Atadja, M. Shultz, Ping Wang, 2012, Drug Metabolism and Disposition.

Conformational refinement of hydroxamate-based histone deacetylase inhibitors and exploration of 3-piperidin-3-ylindole analogues of dacinostat (LAQ824).

P. Atadja, E. Francotte, W. Shao, 2010, Journal of medicinal chemistry.

Novel hydroxamic acid-derived HDAC inhibitor LBH589 potently activates intrinsic and extrinsic apoptotic pathways, and induces tubulin hyperacetylation in multiple myeloma.

N. Munshi, P. Atadja, P. Tassone, 2005 .

Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90

James Bradner, J. Bradner, P. Atadja, 2005, Journal of Biological Chemistry.

Combination of Pan-Histone Deacetylase Inhibitor and Autophagy Inhibitor Exerts Superior Efficacy against Triple-Negative Human Breast Cancer Cells

P. Atadja, K. Bhalla, S. Hembruff, 2012, Molecular Cancer Therapeutics.

Discovery of Small-Molecule Antagonists of the H3K9me3 Binding to UHRF1 Tandem Tudor Domain

P. Atadja, E. Li, C. Arrowsmith, 2018, SLAS discovery : advancing life sciences R & D.

HDAC Inhibitor Panobinostat Engages Host Innate Immune Defenses to Promote the Tumoricidal Effects of Trastuzumab in HER2+ Tumors.

P. Atadja, J. Trapani, R. Johnstone, 2017, Cancer research.

Gaps in Laboratory Quality Management Systems in the Volta Region of Ghana

P. Atadja, F. Binka, S. Lokpo, 2018 .

Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges.

P. Atadja, 2009, Cancer letters.

Detecting S-adenosyl-L-methionine-induced conformational change of a histone methyltransferase using a homogeneous time-resolved fluorescence-based binding assay.

Mathias Frederiksen, P. Atadja, Edmund M. Harrington, 2012, Analytical biochemistry.

Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo

P. Atadja, E. Weisberg, S. Remiszewski, 2004, Leukemia.

Histone deacetylase inhibitor NVP-LAQ 824 has significant activity against myeloid leukemia cells in vitro and in vivo

P. Atadja, E. Weisberg, S. Remiszewski, 2004 .

The Histone Deacetylase Inhibitor NVP-LAQ824 Inhibits Angiogenesis and Has a Greater Antitumor Effect in Combination with the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK787/ZK222584

Lu Zhang, Roberto Pili, Xiaofei Wang, 2004, Cancer Research.

Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.

J. Sarkaria, P. Atadja, D. Wigle, 2008, Neuro-oncology.

Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells.

Song Liu, P. Atadja, Dan Wang, 2011, Free radical biology & medicine.

Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells

P. Atadja, K. Bhalla, S. Upadhyay, 2009, Cancer biology & therapy.

High Efficacy of Panobinostat Towards Human Gastrointestinal Stromal Tumors in a Xenograft Mouse Model

P. Atadja, R. Sciot, G. Floris, 2009, Clinical Cancer Research.

Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation

P. Atadja, E. Li, S. Chuai, 2012, Proceedings of the National Academy of Sciences.

Regulation of gene expression and transcription factor binding activity during cellular aging.

P. Atadja, K. Riabowol, M. Meyyappan, 1996, Biological signals.

Increased activity of p53 in senescing fibroblasts.

P. Atadja, I. Garkavtsev, K. Riabowol, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Overexpression of cyclin D1 blocks proliferation of normal diploid fibroblasts.

P. Atadja, K. Riabowol, H. Wong, 1995, Experimental cell research.

Histone methyltransferase SETDB1 regulates liver cancer cell growth through methylation of p53

Jidong Zhu, P. Atadja, E. Li, 2015, Nature Communications.

Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells

P. Atadja, K. Bhalla, J. Tao, 2012, Clinical Cancer Research.

Cancer Therapy : Preclinical Superior Ef fi cacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells

P. Atadja, K. Bhalla, J. Tao, 2012 .

Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B.

P. Atadja, H. Yamaguchi, K. Bhalla, 2003, Molecular cancer therapeutics.

Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.

Huidong Shi, P. Atadja, K. Bhalla, 2009, Blood.

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

Srinivas Annavarapu, P. Atadja, A. Scuto, 2005, Blood.

Upregulation of CD11b and CD86 through LSD1 inhibition promotes myeloid differentiation and suppresses cell proliferation in human monocytic leukemia cells.

P. Atadja, E. Li, Zongyao Wang, 2017, Oncotarget.

Histone Demethylase LSD1 Promotes Adipocyte Differentiation through Repressing Wnt Signaling.

Yong Zhang, P. Atadja, E. Li, 2016, Cell chemical biology.

SETDB1 modulates PRC2 activity at developmental genes independently of H3K9 trimethylation in mouse ES cells

Yong Zhang, P. Atadja, E. Li, 2015, Genome research.

Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells

A. Chinnaiyan, P. Atadja, K. Bhalla, 2006, Molecular Cancer Therapeutics.

cell death or therapeutic efficacy death receptor signaling or a functional apoptosome to mediate tumor The histone deacetylase inhibitors LAQ824 and LBH589 do not require

Jessica E. Bolden, S. Lowe, A. Strasser, 2010 .

The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy.

Jessica E. Bolden, S. Lowe, A. Strasser, 2009, Blood.

The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines

P. Atadja, M. Prystowsky, Joanna L. Parish, 2009, The Journal of pathology.

HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells.

J. Bradner, P. Atadja, K. Bhalla, 2008, Blood.

Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies.

M. P. Dillon, P. Atadja, E. Li, 2022, Journal of medicinal chemistry.

An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.

P. Atadja, E. Li, Youzhen Wang, 2017, Nature chemical biology.

The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance

P. Atadja, K. Bhalla, K. Wright, 2009, Nature Immunology.

Epigenetics in cancer: Targeting chromatin modifications

Ricky W. Johnstone, P. Atadja, L. Ellis, 2009, Molecular Cancer Therapeutics.

Cloning and Functional Characterization of HDAC11, a Novel Member of the Human Histone Deacetylase Family*

Fred Asselbergs, P. Atadja, F. Asselbergs, 2002, The Journal of Biological Chemistry.

ING1 and 5-Azacytidine Act Synergistically to Block Breast Cancer Cell Growth

P. Atadja, K. Riabowol, Xiaolan Feng, 2012, PloS one.

Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824

P. Atadja, Songshu Meng, Jie Wu, 2005, Molecular Cancer Therapeutics.

The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

P. Atadja, A. Pandiella, Xonia Carvajal-Vergara, 2006, Cancer research.

Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma

Gordon K Smyth, Joachim Beck, Ricky W Johnstone, 2008, Clinical Cancer Research.

Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors.

S. Lowe, J. Zuber, P. Atadja, 2014, Blood.

Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts.

P. Atadja, J. Griffiths, M. Leach, 2008, Neoplasia.

Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells.

P. Atadja, R. Levine, K. Bhalla, 2009, Blood.

Concurrent HDAC and mTORC1 Inhibition Attenuate Androgen Receptor and Hypoxia Signaling Associated with Alterations in MicroRNA Expression

Song Liu, P. Atadja, M. Carducci, 2011, PloS one.

Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism.

P. Atadja, K. Bhalla, Yonghua Yang, 2009, Blood.

Cotreatment with Histone Deacetylase Inhibitor LAQ824 Enhances Apo-2L/Tumor Necrosis Factor-Related Apoptosis Inducing Ligand-Induced Death Inducing Signaling Complex Activity and Apoptosis of Human Acute Leukemia Cells

P. Atadja, K. Bhalla, L. Moscinski, 2004, Cancer Research.

Antitumor activities and on‐target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat

S. Fox, P. Atadja, R. Johnstone, 2011, International journal of cancer.

leukemia cells expressing human - deacetylase inhibitor LBH589 against Bcr-Abl Combined effects of novel tyrosine kinase inhibitor AMN107 and histone

P. Atadja, Jie Wu, K. Bhalla, 2013 .

Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells.

P. Atadja, Jie Wu, K. Bhalla, 2006, Blood.

Discovery and Development of Farydak (NVP-LBH589, Panobinostat) as an Anticancer Drug

P. Atadja, L. Perez, 2016 .

Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors

P. Atadja, A. Tolcher, P. Workman, 2008, Clinical Cancer Research.

Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor–dependent human lung cancer cells

P. Atadja, K. Bhalla, E. Haura, 2007, Molecular Cancer Therapeutics.

Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer.

D. Hallahan, P. Atadja, A. Fu, 2006, Cancer research.

Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of ORAL LBH589B: A novel histone deacetylase (HDAC) inhibitor

P. Atadja, A. Patnaik, C. Huber, 2005 .

HDAC inhibitors and cancer therapy.

P. Atadja, 2011, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

HDAC 6 inhibition enhances 17-AAG – mediated abrogation of hsp 90 chaperone function in human leukemia cells

J. Bradner, P. Atadja, K. Bhalla, 2008 .

Abrogation of MAPK and Akt Signaling by AEE788 Synergistically Potentiates Histone Deacetylase Inhibitor-Induced Apoptosis through Reactive Oxygen Species Generation

P. Atadja, L. Roberts, A. Adjei, 2007, Clinical Cancer Research.

The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide.

P. Atadja, S. Payne, S. Spiegel, 2006, Molecular pharmacology.

Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells

P. Atadja, P. Dent, S. Grant, 2005, Molecular Cancer Therapeutics.

Superior Activity of the Combination of Histone Deacetylase Inhibitor LAQ824 and the FLT-3 Kinase Inhibitor PKC412 against Human Acute Myelogenous Leukemia Cells with Mutant FLT-3

P. Atadja, A. Scuto, S. Annavarapu, 2004, Clinical Cancer Research.

IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms.

P. Atadja, F. Schuit, Lieven Thorrez, 2010, Blood.

Epigenetic modulation of radiation response in human cancer cells with activated EGFR or HER-2 signaling: potential role of histone deacetylase 6.

P. Atadja, E. Bernhard, I. Kim, 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates.

Manfred Jung, W. Cornell, P. Atadja, 2002, Journal of medicinal chemistry.

Preclinical Development Combination of Pan-Histone Deacetylase Inhibitor and Autophagy Inhibitor Exerts Superior Ef fi cacy against Triple-Negative Human Breast Cancer Cells

P. Atadja, K. Bhalla, S. Hembruff, 2012 .

The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair

E. Colado, P. Atadja, A. Pandiella, 2009, Leukemia.

In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.

Paul Workman, Qimin He, E. Lam, 2006, Cancer research.

In vivo Biological Activity of the Histone Deacetylase Inhibitor LAQ824 Is detectable with 3¶-Deoxy-3¶-( 18 F)Fluorothymidine

P. Atadja, P. Workman, D. Vigushin, 2006 .

Hydroxamic Acid Analogue Histone Deacetylase Inhibitors Attenuate Estrogen Receptor-α Levels and Transcriptional Activity: A Result of Hyperacetylation and Inhibition of Chaperone Function of Heat Shock Protein 90

P. Atadja, Yuan Ren, Jie Wu, 2007, Clinical Cancer Research.

Epigenetic Silencing of the Tetraspanin CD9 during Disease Progression in Multiple Myeloma Cells and Correlation with Survival

P. Atadja, X. Leleu, K. Thielemans, 2008, Clinical Cancer Research.

Isolation and Characterization of a Novel Class II Histone Deacetylase, HDAC10*

P. Atadja, F. Asselbergs, D. Cohen, 2002, The Journal of Biological Chemistry.

Inhibition of Histone Deacetylases Promotes Ubiquitin-Dependent Proteasomal Degradation of DNA Methyltransferase 1 in Human Breast Cancer Cells

P. Atadja, N. Davidson, W. Nelson, 2008, Molecular Cancer Research.

Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation

P. Atadja, N. Davidson, Qun Zhou, 2007, Cancer biology & therapy.

The Histone Deacetylase Inhibitor NVP-LAQ 824 Inhibits Angiogenesis and Has a Greater Antitumor Effect in Combination with the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK 787 / ZK 222584

D. Qian, P. Atadja, R. Pili, 2004 .

Upregulation of CD11b and CD86 through LSD1 inhibition promotes myeloid differentiation and suppresses cell proliferation in human monocytic leukemia cells

P. Atadja, E. Li, Zongyao Wang, 2017, Oncotarget.

Polycomb Target Genes Are Silenced in Multiple Myeloma

P. Atadja, K. Nilsson, F. Öberg, 2010, PloS one.

Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma

P. L. Bergsagel, P. Atadja, M. Doyle, 2013, Cell Death and Disease.

LBH589, a novel histone deacetylase inhibitor (HDACi), treatment of patients with cutaneous T-cell lymphoma (CTCL). Changes in skin gene expression profiles related to clinical response following therapy.

P. Atadja, R. Johnstone, D. George, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of LBH589A: A novel histone deacetylase inhibitor

P. Atadja, A. Patnaik, M. Mita, 2004 .

A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors.

P. Atadja, A. Patnaik, M. Mita, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase inhibitor LAQ824 in patients with hematologic malignancies.

P. Sonneveld, P. Atadja, D. DeAngelo, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of the histone deacetylase inhibitor (HDACI) LAQ824 on histone acetylation, Hsp70 and c-Raf in peripheral blood lymphocytes from patients with advanced solid tumours enrolled in a phase I clinical trial.

P. Atadja, P. Workman, I. Judson, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

chaperone function in human leukemia cells HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90

J. Bradner, P. Atadja, K. Bhalla, 2013 .

Synergistic action of the novel HSP90 inhibitor NVP‐AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma

P. Atadja, M. Jensen, C. García-echeverría, 2010, European journal of haematology.

In bcr-abl-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of Par-4 increases sensitivity to imatinib (STI571) and histone deacetylase-inhibitors.

Daniel Nowak, P. Atadja, D. Nowak, 2004, Biochemical pharmacology.

Absolute quantification of histone PTM marks by MRM-based LC-MS/MS.

P. Atadja, E. Li, R. Sack, 2014, Analytical chemistry.

The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.

P. Atadja, L. Urban, Nicole Davis, 2011, Bioorganic & medicinal chemistry letters.

Involvement of Histone Acetylation of Sox17 and Foxa2 Promoters during Mouse Definitive Endoderm Differentiation Revealed by MicroRNA Profiling

P. Atadja, E. Li, S. Chuai, 2011, PloS one.

Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer

A. Maitra, M. Hidalgo, P. Atadja, 2012, Oncotarget.

PSC-833, a frontier in modulation of P-glycoprotein mediated multidrug resistance

P. Atadja, D. Cohen, Toru Watanabe, 1998, Cancer and Metastasis Reviews.

An allosteric PRC 2 inhibitor targeting the H 3 K 27 me 3 binding pocket of EED

P. Atadja, E. Li, Youzhen Wang, 2016 .

Discovery of Potent Small-Molecule Inhibitors of WDR5-MYC Interaction.

Stephen M. Canham, John A. Tallarico, P. Atadja, 2023, ACS chemical biology.

Anti-leukemia activity of histone deacetylase (HDAC) inhibitor LBH589 involves depletion of EZH2 and DNA methyltransferase (DNMT) 1 through disruption of their chaperone association with heat shock protein (hsp) 90

P. Atadja, K. Bhalla, C. Ustun, 2007 .

Triple Combinations of the HDAC Inhibitor Panobinostat (LBH589) + Dexamethasone with Either Lenalidomide or Bortezomib Are Highly Effective in a Multiple Myeloma Mouse Model.

J. Miguel, P. Atadja, A. Pandiella, 2007 .

Pan-Histone Deacetylase (HDAC) Inhibitor LBH589 Depletes CXCR4 Levels and Signaling, Exerting Synergistic Anti-Leukemia Activity in Combination with CXCR4 Antagonists.

P. Atadja, K. Bhalla, N. Fujii, 2007 .

Current trends in outwitting resistance development in Candida infections through photodynamic and short peptide therapies: a strategic-shift from conventional antifungal agents

P. Atadja, S. D. Waikhom, Bengyella Louis, 2016, Expert review of anti-infective therapy.

Combination Strategy Targeting the Hypoxia Inducible Factor-1α with Mammalian Target of Rapamycin and Histone Deacetylase Inhibitors

D. Qian, P. Atadja, H. Verheul, 2008, Clinical Cancer Research.

Role of CAAT/Enhancer Binding Protein Homologous Protein in Panobinostat-Mediated Potentiation of Bortezomib-Induced Lethal Endoplasmic Reticulum Stress in Mantle Cell Lymphoma Cells

P. Atadja, K. Bhalla, J. Tao, 2010, Clinical Cancer Research.

Gene et proteine associes aux histones desacetylases

P. Atadja, Lin Gao, M. Cueto, 2002 .

Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia

J. Zuber, P. Atadja, R. Johnstone, 2015, Clinical Epigenetics.

Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.

Huidong Shi, P. Atadja, K. Bhalla, 2009, Blood.

Epigenetics in cancer: Targeting chromatin modifications

P. Atadja, L. Ellis, R. Johnstone, 2009, Molecular Cancer Therapeutics.

Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer

A. Maitra, M. Hidalgo, P. Atadja, 2012, Oncotarget.

The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.

P. Atadja, L. Urban, Nicole Davis, 2011, Bioorganic & medicinal chemistry letters.

The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells.

P. Atadja, R. Jove, Y. Yen, 2007, Blood.

The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy.

Jessica E. Bolden, S. Lowe, A. Strasser, 2009, Blood.

A phase I study of oral panobinostat (LBH589) alone and in combination with docetaxel (Doc) and prednisone in castration-resistant prostate cancer (CRPC)

P. Atadja, H. Scher, D. Rathkopf, 2008 .

HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells.

J. Bradner, P. Atadja, K. Bhalla, 2008, Blood.

LBH589, a Novel Deacetylase Inhibitor (DACi), Treatment of Patients with Cutaneous T-Cell Lymphoma (CTCL). Skin Gene Expression Profiles in the First 24 Hours Related to Clinical Response Following Therapy.

P. Atadja, L. Ellis, R. Johnstone, 2006 .

Role of CAAT/Enhancer Binding Protein Homologous Protein in Panobinostat-Mediated Potentiation of Bortezomib-Induced Lethal Endoplasmic Reticulum Stress in Mantle Cell Lymphoma Cells

P. Atadja, K. Bhalla, J. Tao, 2010, Clinical Cancer Research.